Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jason Haas Insider Profile
4 Followers
Jason Haas, CFO at Syros Pharmaceuticals, holds 0.00 shares in Syros Pharmaceuticals (Ticker: SYRS), holds 5.40K shares in Ligand Pharma (Ticker: LGND). Most recently, Jason Haas Sold ― shares of Syros Pharmaceuticals on Nov 20, 2024 for an estimated value of 28.94K.
Jason Haas has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Jason Haas
Jason Haas's Trading History
Syros Pharmaceuticals
Nov 20, 2024
CFO
Informative Sell
28.94K
$0.00
Ligand Pharma
Jun 18, 2024
Director
Uninformative Buy
―
$629.02K
List of latest transactions for each holding click on a transaction to see Jason Haas's performance on stock
You May Also Like
Jason Haas insider profile FAQ
What is the percentage of profitable transactions made by Jason Haas?
The percentage of profitable transactions made by Jason Haas is ―.
What is the average return per transaction made by Jason Haas?
The average return per transaction made by Jason Haas is ―.
What stocks does Jason Haas hold?
Jason Haas holds: SYRS, LGND stocks.
What was Jason Haas’s latest transaction?
Jason Haas latest transaction was an Informative Sell of $28.94K.
What was Jason Haas's most profitable transaction?
Jason Haas’s most profitable transaction was an Informative Buy of SYRS stock on September 12, 2024. The return on the trade was 66.20%.
What is Jason Haas's role in Syros Pharmaceuticals?
Jason Haas's role in Syros Pharmaceuticals is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.